Read more at: https://www.ndtvprofit.com/business/biocon-onboards-local-partner-for-diabetes-drug-in-brazil
Biotechnology firm Biocon Ltd. on Wednesday said it has tied up with Brazil-based Biomm SA for the commercialisation of its diabetes drug in the Latin American nation. Under the terms of the agreement, Biocon will undertake the development, manufacturing and supply of Semaglutide (gOzempic), and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian mark
Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at its production facility in Nova Lima.
‘Our partnership with Biomm marks another important step forward in our strategy to expand our global footprint beyond the US and Europe for Peptides,’ Biocon CEO and MD Siddharth Mittal said in a statement.
This is also in line with the growth strategy of bringing to market a portfolio of complex, GLP-1 drug-device combination products, he added.